These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 22575028)
1. Characteristics of persons who complied with and failed to comply with annual ivermectin treatment. Brieger WR; Okeibunor JC; Abiose AO; Ndyomugyenyi R; Wanji S; Elhassan E; Amazigo UV Trop Med Int Health; 2012 Jul; 17(7):920-30. PubMed ID: 22575028 [TBL] [Abstract][Full Text] [Related]
2. Intention to continue with ivermectin treatment for onchocerciasis control after eight years of annual distribution in Cameroon, Nigeria, and Uganda. Okeibunor JC; Brieger WR; Abiose AO; Elhassan E; Ndyomugyenyi R; Wanji S; Amazigo UV Int Q Community Health Educ; 2012-2013; 33(2):159-73. PubMed ID: 23661417 [TBL] [Abstract][Full Text] [Related]
3. Compliance with eight years of annual ivermectin treatment of onchocerciasis in Cameroon and Nigeria. Brieger WR; Okeibunor JC; Abiose AO; Wanji S; Elhassan E; Ndyomugyenyi R; Amazigo UV Parasit Vectors; 2011 Jul; 4():152. PubMed ID: 21794139 [TBL] [Abstract][Full Text] [Related]
4. After a decade of annual dose mass ivermectin treatment in Cameroon and Uganda, onchocerciasis transmission continues. Katabarwa M; Eyamba A; Habomugisha P; Lakwo T; Ekobo S; Kamgno J; Kuete T; Ndyomugyenyi R; Onapa A; Salifou M; Ntep M; Richards FO Trop Med Int Health; 2008 Sep; 13(9):1196-203. PubMed ID: 18631308 [TBL] [Abstract][Full Text] [Related]
5. Where would I be without ivermectin? Capturing the benefits of community-directed treatment with ivermectin in Africa. Okeibunor JC; Amuyunzu-Nyamongo M; Onyeneho NG; Tchounkeu YF; Manianga C; Kabali AT; Leak S Trop Med Int Health; 2011 May; 16(5):608-21. PubMed ID: 21395925 [TBL] [Abstract][Full Text] [Related]
6. Still mesoendemic onchocerciasis in two Cameroonian community-directed treatment with ivermectin projects despite more than 15 years of mass treatment. Kamga GR; Dissak-Delon FN; Nana-Djeunga HC; Biholong BD; Mbigha-Ghogomu S; Souopgui J; Zoure HG; Boussinesq M; Kamgno J; Robert A Parasit Vectors; 2016 Nov; 9(1):581. PubMed ID: 27842567 [TBL] [Abstract][Full Text] [Related]
7. The community-based treatment of onchocerciasis in Shao, Kwara State, Nigeria. Oyibo WA; Fagenro-Beyioku AF Southeast Asian J Trop Med Public Health; 2002 Sep; 33(3):496-503. PubMed ID: 12693582 [TBL] [Abstract][Full Text] [Related]
8. Predictors of compliance with community-directed ivermectin treatment in Uganda: quantitative results. Nuwaha F; Okware J; Ndyomugyenyi R Trop Med Int Health; 2005 Jul; 10(7):659-67. PubMed ID: 15960704 [TBL] [Abstract][Full Text] [Related]
9. Factors Associated with Ivermectin Non-Compliance and Its Potential Role in Sustaining Onchocerca volvulus Transmission in the West Region of Cameroon. Senyonjo L; Oye J; Bakajika D; Biholong B; Tekle A; Boakye D; Schmidt E; Elhassan E PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004905. PubMed ID: 27529622 [TBL] [Abstract][Full Text] [Related]
10. Proteinuria and onchocerciasis in an endemic area in Cameroon under community-based treatment with ivermectin. Ebong CE; Alemnji GA; ; Ashuntantang G; Asonganyi T Trop Doct; 2007 Jul; 37(3):156-8. PubMed ID: 17716503 [TBL] [Abstract][Full Text] [Related]
11. Community-based treatment of onchocerciasis with ivermectin in southwest Nigeria: dermatological response to a singledose therapy. Osungbade KO; Asuzu MC; Kale OO Afr J Med Med Sci; 2001 Dec; 30(4):352-5. PubMed ID: 14510119 [No Abstract] [Full Text] [Related]
12. Field-Based Evidence of Single and Few Doses of Annual Ivermectin Treatment Efficacy in Eliminating Skin Microfilaria Load after a Decade of Intervention. Osue HO Ethiop J Health Sci; 2017 Mar; 27(2):129-138. PubMed ID: 28579708 [TBL] [Abstract][Full Text] [Related]
13. Predictors of compliance with community-directed treatment with ivermectin for onchocerciasis control in Kabo area, southwestern Ethiopia. Endale A; Erko B; Weldegebreal F; Legesse M Parasit Vectors; 2015 Feb; 8():99. PubMed ID: 25890151 [TBL] [Abstract][Full Text] [Related]
14. Community response to repeated annual ivermectin treatment of onchocerciasis in Nigeria. Oyibo WA; Fagbenro-Beyioku AF Parasitol Res; 2002 Jul; 88(7):704-7. PubMed ID: 12107465 [TBL] [Abstract][Full Text] [Related]
15. Impact of 3 years ivermectin treatment on onchocerciasis in Yanomami communities in the Brazilian Amazon. Banic DM; Calvão-Brito RH; Marchon-Silva V; Schuertez JC; de Lima Pinheiro LR; da Costa Alves M; Têva A; Maia-Herzog M Acta Trop; 2009 Nov; 112(2):125-30. PubMed ID: 19615327 [TBL] [Abstract][Full Text] [Related]
16. Adverse reactions to ivermectin treatment in Simulium neavei-transmitted onchocerciasis. Kipp W; Bamhuhiiga J; Rubaale T; Büttner DW Am J Trop Med Hyg; 2003 Dec; 69(6):621-3. PubMed ID: 14740878 [TBL] [Abstract][Full Text] [Related]
17. Adverse reactions from community directed treatment with ivermectin (CDTI) for onchocerciasis and loiasis in Ondo State, Nigeria. Otubanjo OA; Adeoye GO; Ibidapo CA; Akinsanya B; Okeke P; Atalabi T; Adejai ET; Braide E Rev Biol Trop; 2008 Dec; 56(4):1635-43. PubMed ID: 19419072 [TBL] [Abstract][Full Text] [Related]
18. Primary motives for demand of ivermectin drug in mass distribution programmes to control onchocerciasis. Abanobi OC; Chukwuocha UM; Onwuiiliri CO; Opara KC East Afr J Public Health; 2011 Mar; 8(1):33-7. PubMed ID: 22066280 [TBL] [Abstract][Full Text] [Related]
19. Adherence to ivermectin is more associated with perceptions of community directed treatment with ivermectin organization than with onchocerciasis beliefs. Dissak-Delon FN; Kamga GR; Humblet PC; Robert A; Souopgui J; Kamgno J; Essi MJ; Ghogomu SM; Godin I PLoS Negl Trop Dis; 2017 Aug; 11(8):e0005849. PubMed ID: 28806785 [TBL] [Abstract][Full Text] [Related]
20. Prevalence of onchocerciasis, attitudes and practices and the treatment coverage after 15 years of mass drug administration with ivermectin in the Tombel Health District, Cameroon. Nyagang SM; Cumber SN; Cho JF; Keka EI; Nkfusai CN; Wepngong E; Tsoka-Gwegweni JM; Fokam EB Pan Afr Med J; 2020; 35():107. PubMed ID: 32637005 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]